Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen–related apple allergy, , , , , , , , , , Barbara BohlexBarbara BohleSearch for articles by this authorAffiliationsDepartment of Pathophysiology and Allergy Research and Christian Doppler Laboratory for Immunomodulation, Medical University of Vienna, Vienna, AustriaCorrespondenceCorresponding author: Barbara Bohle, PhD, Medical University of Vienna, Department of...